首页> Neuropharmacology> The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

导出原文传递

翻译打印收藏纠错

第一作者： Amit, Tamar

作者： Amit, Tamar ^[1] ; Bar-Am, Orit ; Mechlovich, Danit ; Kupershmidt, Lana ; Youdim, Moussa B. H. ; Weinreb, Orly

作者单位： Technion Israel Inst Technol, Fac Med, POB 9697, IL-31096 Haifa, Israel ^[1]

关键词 Alzheimer's disease APP processing/regulation Amyloid beta Iron chelation Propargyl moiety

发布时间 2018-02-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Neuropharmacology

2017年123卷

359-367页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Neuropharmacology

2017年123卷

359-367页

检索历史清除

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

Neuropharmacology

相似文献

同项目论文

Neuropharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models

Neuropharmacology

相似文献

同项目论文

Neuropharmacology

相关期刊

检索历史清除